M. Osowiecki

发表

Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma

A. Florek, J. Zaucha, W. Knopińska-Posłuszny, 2016, American journal of therapeutics.

High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up

J. Walewski, A. Borawska, J. Romejko-Jarosińska, 2022, Scientific Reports.

Primary central nervous system lymphoma — a review of current therapeutic strategies

J. Walewski, M. Osowiecki, B. Ostrowska, 2015 .

Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors.

J. Zaucha, A. Waszczuk-Gajda, B. Puła, 2020, Advances in medical sciences.

Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study

J. Zaucha, T. Robak, K. Giannopoulos, 2020, AntiCancer Research.

FcγRIIA and FcγRIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma

J. Siedlecki, J. Walewski, E. Paszkiewicz-Kozik, 2011, Leukemia & lymphoma.

Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy

W. Jędrzejczak, A. Nagler, P. Smolewski, 2004, Bone Marrow Transplantation.

Two autologous transplants in the treatment of patients with Hodgkin's lymphoma: Analysis of prognostic factors and comparison with a single procedure

R. Dziadziuszko, J. Czyż, A. Skotnicki, 2007, Leukemia & lymphoma.

Plerixafor for patients who fail cytokine-or chemotherapy-based stem cell mobilization: Results of a prospective study by the Polish Lymphoma Research Group (PLRG)

J. Drozd-Sokołowska, J. Romejko-Jarosińska, E. Paszkiewicz-Kozik, 2018, Acta Haematologica Polonica.

Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients.

K. Sułek, R. Dziadziuszko, A. Nagler, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation‐ineligible relapsed and refractory diffuse large B‐cell lymphoma

J. Zaucha, J. Walewski, A. Pluta, 2022, British journal of haematology.

Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine (R‐MIV) in patients with primary CNS lymphoma including recent COVID‐19 pandemic experience

J. Walewski, A. Borawska, J. Romejko-Jarosińska, 2023, British journal of haematology.

Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma.

J. Zaucha, K. Giannopoulos, A. Pasternak, 2019, Advances in medical sciences.